Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349973 · ClinicalTrials.gov registry record · NA
Clinical Trial of Dipyridamole in Schizophrenia
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT00349973 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 29 participants.
The verdict
NCT00349973, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform disorder. This pilot study aims to provide preliminary estimates of whether the effect sizes of dipyridamole on positive symptoms, negative symptoms, and cognitive deficits differ between schizophrenia patients treated with dipyridamole, and schizophrenia patients treated with olanzapine. A total of 30 subjects will be recruited locally.
Interventions
- OTHER Olanzapine
- DRUG Dipyridamole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2001-05 |
| Est. Completion | 2011-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00349973
The ClinicalTrials.gov registry entry for NCT00349973 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00349973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00349973 about?
NCT00349973 is a clinical study titled "Clinical Trial of Dipyridamole in Schizophrenia". This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform disorder. This pilot study aims to provide preliminary estimates of whether t...
What is the current status of trial NCT00349973?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2001-05. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00349973?
The interventions under investigation include: Olanzapine (OTHER), Dipyridamole (DRUG).
Who is sponsoring clinical trial NCT00349973?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.